Thursday, October 15, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 19, 2026

Why Billionaire Investor Druckenmiller Sees Stablecoins Dominating Payments In The Next 10 To 15 Years

View original at finance.yahoo.com
Why Billionaire Investor Druckenmiller Sees Stablecoins Dominating Payments In The Next 10 To 15 Years Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Payment systems will be dominated by stablecoins in 10 to 15 years

    60% confidence

  • Blockchain and stablecoins are incredibly useful for productivity

    60% confidence

  • No longer holds Bitcoin as of 2022 due to quantitative tightening

    60% confidence

  • Crypto has gained traction and will be a store of value

    60% confidence

  • Global payment systems will be stablecoins in 10 to 15 years

    60% confidence

  • Bitcoin was purchased as a high-beta gold play

    60% confidence

  • Bought Bitcoin in 2020 as a high-beta gold play

    60% confidence

  • Some crypto thing could replace the U.S. dollar as the global reserve currency

    60% confidence

  • No longer held Bitcoin in 2022 due to quantitative tightening by central banks

    60% confidence

  • Some cryptocurrency could replace the U.S. dollar as global reserve currency

    60% confidence

  • Cryptocurrency is a solution looking for a problem

    60% confidence

  • Crypto is a solution looking for a problem

    60% confidence

  • Blockchain and stablecoins are incredibly useful in terms of productivity

    60% confidence

  • Cryptocurrency will be a store of value due to gained traction

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Why Billionaire Investor Druckenmiller Sees Stablecoins Dominating Payments In The Next 10 To 15 Years — Source | Via News | Via News